Serotonin agonists can reduce glutamate-induced excitotoxicity in cerebral ischemia. The potent 5-HT1A agonist BAY × 3702, or repinotan, has reduced cortical infarct volume in pre-clinical models even when given 5 hours after injury. Early clinical trials showed that the drug was safe, and displayed primarily serotonergic side effects such as nausea and vomiting. A phase IIb trial in moderate to moderately severe strokes completed enrollment in June 2004.
|Original language||English (US)|
|Number of pages||2|
|Journal||Current Drug Targets: CNS and Neurological Disorders|
|State||Published - Apr 2005|
- Acute stroke treatment
ASJC Scopus subject areas